Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0036572 (seizures)
 80,221 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effect of vitamin E and clobazam on lipid peroxides [LP] in the rat brain and the pattern of electroshock-induced seizures were assessed. Significant increase in the concentration of brain LP at the peak of seizures was found. Both vitamin E and clobazam reduced the levels of LP in the rat brain after electroshock. Clobazam combined with vitamin E inhibited markedly formation of LP in the rats with electroshock-induced seizures. Vitamin E augmented anticonvulsant effect of clobazam though itself it had not exhibited any anticonvulsant effect in this model of seizures. The action of two drugs combined resulted in reducing the intensity and the duration of seizures, and only minimal seizures were observed. In our opinion the obtained results possess some interesting clinical aspect They suggest that the combined treatment with clobazam and vitamin E of epileptic patient may decrease the intensity of epileptic seizures due to inhibition of LP formation.
 ...
PMID:Effects of clobazam and vitamin E on the lipid peroxidation in the rat brain after electroconvulsive shock. 1069 28

Clobazam (0.5 to 7.5 mg/kg i.p.) was tested against motor seizures elicited by pentylenetetrazol in rats 7, 12, 18, 25 and 90 days old. Minimal, predominantly clonic seizures with preserved righting ability were reliably induced by pentylenetetrazol and suppressed by clobazam in rats aged 18 days or more. The incidence of minimal seizures after clobazam pretreatment was not increased in 7- and 12-day-old rat pups. Generalized tonic-clonic seizures were markedly suppressed by clobazam in all age groups. In 18-day-old and older animals clobazam doses suppressing generalized seizures were always lower than those necessary for exerting an effect on minimal seizures. The differences in clobazam action appearing at various levels of maturation are only quantitative.
 ...
PMID:Antipentylenetetrazol action of clobazam in developing rats. 1078 16

Clobazam (CLB) is a new antiepileptic drug that is the first 1,5-benzodiazepine (BZP) having nitrogen atoms in the 1 and 5 positions of the heterocyclic ring, whose chemical structure was designed to give it a different pharmacological profile from that of 1,4-BZPs. Although CLB has a Ki value of 2,130 nM and thus has a lower affinity for the BZP receptor than 1,4-BZPs, it had the selectivity to omega 2 receptor contributing to anticonvulsive actions compared with omega 1 receptor in relation to other CNS activities such as sedation. CLB had a wide spectrum of anticonvulsive actions against seizures in several animal models induced by chemical convulsants and maximal electroshock. CLB reduced both seizure stage and afterdischarge duration in a dose-dependent manner in amygdala or hippocampal kindled rats. Usefulness of an anticonvulsant is generally assessed by quoting the protective index (PI) in the ratio of TD50 to ED50. As the PI for CLB was greater than that for 1,4-BZPs, it suggested that CLB was superior to 1,4-BZPs in tolerability while showing anticonvulsive actions. In clinical studies, CLB was used as an adjunctive treatment in patients with refractory epilepsies. From both experimental and clinical observations, CLB was proven to possess a wide spectrum of activity, high effectiveness and good tolerability in several types of epilepsies.
 ...
PMID:[A pharmacological profile of clobazam (Mystan), a new antiepileptic drug]. 1153 Jun 81

Clobazam (CLB) add-on therapy was attempted in 183 patients with intractable complex partial seizures in whom conventional benzodiazepines had been successfully discontinued before initiation of CLB. Although complete remission was initially achieved in 61, tolerance developed in almost half (49.2%) within the first 3 months, whereas 23 out of 31 patients (74.2%) who remained seizure free for the first 3 months continued to be so over the next 3 months. CLB add-on therapy proved to be significantly more effective when concurrent GTC occurred more often than yearly. In the current series, no frank psychotic episodes were elicited among the 61 patients who achieved complete suppression of long-standing complex partial seizures, which was in agreement with previous studies. From these results, we believe that CLB is an effective, safe, and inexpensive medication for add-on therapy in difficult to treat focal epilepsies, especially without concurrent use of conventional benzodiazepine compounds.
Seizure 2003 Jul
PMID:Use of clobazam for the treatment of refractory complex partial seizures. 1281 Mar 40

Photosensitivity is an abnormal visual sensitivity of the brain in reaction to flickering light sources or patterns and is expressed in the electroencephalogram as generalized spike-and-wave discharge and in more susceptible individuals as clinical seizures. The most common types of seizures are generalized tonic-clonic, followed by myoclonic and absence. The photosensitive epilepsies are classified as pure photosensitive, where seizures occur only with the flickering light source/pattern or during intermittent photic stimulation (IPS) in the laboratory, and epilepsy with photosensitivity, where spontaneous seizures also occur. Positive response to IPS in idiopathic epilepsy syndromes, which are included in the International Classification or are in development, is reported to range from 7.5% in juvenile absence epilepsy to 100% in pure photosensitive epilepsy. The treatment of photosensitivity and pure photosensitive epilepsy with rare seizures includes general and specific protective measures. For most patients, however, combination treatment with antiepileptic drugs is necessary. Valproic acid monotherapy has a success rate of 73-86%. Levetiracetam appears to be a new alternative therapeutic option. Clobazam, lamotrigine, ethosuximide, and topiramate also have been recommended as second-choice therapies.
 ...
PMID:Photosensitivity in idiopathic generalized epilepsies. 1630 77

A four-year-old male with symptomatic generalized epilepsy presented with ataxia, eye rolling, and episodes of back arching which were of non-epileptic origin following the introduction of clobazam at 0.75mg/kg/day. Concurrent antiepileptic medication was lamotrigine at 13mg/kg/day. Clobazam plasma levels were within the normal range, while N-desmethylclobazam (DCLB) concentrations were between five and seven times above the upper limit of the normal range. The plasma elimination half-life for DCLB was prolonged, suggesting a genetic variability in DCLB metabolism leading to toxicity. Reduction in the dose of clobazam to 0.3mg/kg/day was associated with resolution of the non-epileptic neurological symptoms, reduction in DCLB plasma levels, and maintenance of seizure control.
 ...
PMID:Eye rolling as a manifestation of clobazam toxicity in a child with epilepsy. 1678 Jun 34

The objective of this study was to evaluate the safety and efficacy of clobazam in children with refractory focal epilepsy. We investigated 100 consecutive patients concerning etiology of epilepsy, previously used antiepileptic drugs, seizure frequency and adverse events. Clobazam was introduced as add-on therapy in patients with previous failure of at least two monotherapies. Mean age was eight years-old and 39 patients were girls. Clobazam mean dosage was 23.6 mg/day. Mean use of clobazam was 18.6 months. Twenty-two patients had adverse events. Twenty-six patients became seizure-free, 11 had an improvement of >75% and in 58 there was no modification in seizure frequency. Five patients had an increase in seizure frequency. Clobazam efficacy lasted for more than one year in 42% of the seizure-free patients. Clobazam seems to be safe and effective in the treatment of focal epilepsy in childhood and should be considered in patients with refractory seizures.
 ...
PMID:Effectiveness of clobazam as add-on therapy in children with refractory focal epilepsy. 1705 71

Catastrophic childhood epilepsies such as infantile spasms (IS), progressive myoclonic epilepsy, and Lennox-Gastaut syndrome (LGS) are rare but debilitating and frequently persist into adulthood. Early, targeted use of medications that have demonstrated efficacy in the management of LGS or its associated epilepsies may simplify the patient's treatment regimen and reduce the incidence of adverse events. Key to the overall benefit to the patient is to maximize seizure control while minimizing adverse effects, especially behavioral and cognitive problems. Clobazam has demonstrated clinical benefit and has been administered safely in more than 50 European studies in which data were reported on greater than 3000 pediatric and adult patients with epilepsy, 300 of whom were diagnosed with LGS; therefore, its use is now being investigated in the U.S. This review will explore the use of clobazam in the treatment of epilepsy, particularly with regard to its potential benefit in LGS. Though not currently approved for use in the U.S., a program is underway to gain Food and Drug Administration approval for the treatment of pediatric and adult patients with refractory epilepsy, specifically in LGS. A phase 2 study will be completed in late 2006 to investigate the safety and efficacy of clobazam as adjunctive therapy in 68 pediatric and adult patients with LGS.
 ...
PMID:Clobazam. 1719 29

The antiepileptic effect of clobazam was first described in 1973. The main advantages of clobazam as an antiepileptic drug are its fast-onset of action and effect against a wide variety of seizures. Despite sometimes losing its effectiveness after a previous period in which it has been effective, clobazam may keep its antiepileptic effect when used intermittently. Tolerance is much more common with benzodiazepines than the other antiepileptic drugs. Although tolerance to clobazam does occur, sustained responders have been identified, and many patients maintain their controlled seizures for several months. Clobazam is a safe drug, and its efficacy is probably equivalent to that of the new antiepileptic drugs. Therefore, it should be considered as add-on medication in the treatment of epilepsy. Clobazam is rapidly and completely absorbed and can be used intermittently, especially for catamenial epilepsy and in patients with clusters of seizures, but only during periods of seizure exacerbation.
 ...
PMID:Role of clobazam in the treatment of epilepsies. 1981 Aug 86

The aim of the present investigation was to prepare and characterize clobazam mucoadhesive microemulsion (CZMME) to assess brain drug uptake and protection against pentylenetetrazole (PTZ)-induced convulsions in mice. Clobazam microemulsion (CZME) and CZMME were prepared by titration method and characterized. Brain uptake and pharmacokinetic parameters were calculated from drug concentration in mice brain versus time plots following intranasal administration of radiolabeled CZME and CZMME, intravenous and intranasal administration of radiolabeled clobazam solution. Gamma scintigraphy imaging of rabbit brain following intranasal administration was performed. Formulations were investigated for the onset of seizures in PTZ-challenged mice. Brain targeting efficiency and direct nose-to-brain transport percentage for mucoadhesive microemulsion suggested an improved brain uptake following intranasal administration. The findings were supported by gamma scintigraphy images. Delay in onset of PTZ-induced seizures with CZMME compared with positive control and placebo-treated groups confirmed the improved brain uptake. However, extensive animal studies followed by clinical trials are necessary to develop a product suitable for emergencies of acute seizures in status epilepticus and patients suffering from drug tolerance and hepatic impairment on long-term use in treatment of epilepsy, schizophrenia, and anxiety.
 ...
PMID:Intranasal clobazam delivery in the treatment of status epilepticus. 2079 66


<< Previous 1 2 3 4 5 6 7 Next >>